Sebastian Podlipnik1, Cristina Carrera1, Marcelo Sánchez2, Pedro Arguis2, Maria L Olondo2, Ramon Vilana2, Ramon Rull3, Sergi Vidal-Sicart4, Antonio Vilalta5, Carles Conill6, Josep Malvehy1, Susana Puig7. 1. Dermatology Department, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) on Rare Disease, Instituto de Salud Carlos III, Barcelona, Spain. 2. Radiology Service, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 3. Surgery Department, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 4. Nuclear Medicine Service, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 5. Dermatology Department, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 6. Radiotherapy Oncology, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 7. Dermatology Department, Melanoma Unit, Hospital Clinic, and Ititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) on Rare Disease, Instituto de Salud Carlos III, Barcelona, Spain. Electronic address: spuig@clinic.ub.es.
Abstract
BACKGROUND: There is no international consensus on optimal follow-up schedules and which supplementary tests should be used after resection of a primary melanoma. OBJECTIVE: We sought to analyze the performance of the follow-up components and identify procedures that detect melanoma metastasis earlier. METHODS: This was a prospective cohort from 290 consecutive patients given a diagnosis of stage IIB, IIC, and III melanoma. Patients were followed up with an intensive protocol based on imaging studies (computed tomography of the chest, abdomen, and pelvis, and brain magnetic resonance imaging), periodic laboratory tests, regular physical examinations, and patient self-examinations. RESULTS: A total of 2382 clinical examinations and 3069 imaging tests were performed. The patients completed 899.8 person-years of follow-up, with a median of 2.5 years. In all, 115 recurrences in 290 patients were recorded, of which computed tomography detected 48.3%; brain magnetic resonance imaging, 7.6%; laboratory test, 2.5%; physician, 23.7%; and patient, 17.8%. LIMITATIONS: Patients with stage III melanoma were not systematically classified into subgroups and overall survival was not evaluated. CONCLUSION: We observed that this intensive monitoring is appropriate for early detection of recurrence in stage IIB, IIC, and III melanoma. Prompt diagnosis of metastasis and the recent development of new therapeutic targets may improve overall survival.
BACKGROUND: There is no international consensus on optimal follow-up schedules and which supplementary tests should be used after resection of a primary melanoma. OBJECTIVE: We sought to analyze the performance of the follow-up components and identify procedures that detect melanoma metastasis earlier. METHODS: This was a prospective cohort from 290 consecutive patients given a diagnosis of stage IIB, IIC, and III melanoma. Patients were followed up with an intensive protocol based on imaging studies (computed tomography of the chest, abdomen, and pelvis, and brain magnetic resonance imaging), periodic laboratory tests, regular physical examinations, and patient self-examinations. RESULTS: A total of 2382 clinical examinations and 3069 imaging tests were performed. The patients completed 899.8 person-years of follow-up, with a median of 2.5 years. In all, 115 recurrences in 290 patients were recorded, of which computed tomography detected 48.3%; brain magnetic resonance imaging, 7.6%; laboratory test, 2.5%; physician, 23.7%; and patient, 17.8%. LIMITATIONS: Patients with stage III melanoma were not systematically classified into subgroups and overall survival was not evaluated. CONCLUSION: We observed that this intensive monitoring is appropriate for early detection of recurrence in stage IIB, IIC, and III melanoma. Prompt diagnosis of metastasis and the recent development of new therapeutic targets may improve overall survival.
Authors: Mark William Linder; Michael E Egger; Tracy Van Meter; Shesh N Rai; Roland Valdes; Melissa Barousse Hall; Xiaoyong Wu; Norah Alghamdi; Jason A Chesney Journal: Mol Diagn Ther Date: 2021-05-10 Impact factor: 4.074
Authors: Aaron W Kangas-Dick; Alissa Greenbaum; Victor Gall; Roman Groisberg; Janice Mehnert; Chunxia Chen; Dirk F Moore; Adam C Berger; Vadim Koshenkov Journal: Ann Surg Oncol Date: 2021-01-23 Impact factor: 5.344
Authors: Kok Haw Jonathan Lim; Lavinia Spain; James M Larkin; Paul Lorigan; Claire Barker; Alexandros Georgiou; Gerard Walls; Martin Gore; Samra Turajlic; Ruth Board Journal: ESMO Open Date: 2018-02-24
Authors: Eddy C Hsueh; James R DeBloom; Jonathan Lee; Jeffrey J Sussman; Kyle R Covington; Brooke Middlebrook; Clare Johnson; Robert W Cook; Craig L Slingluff; Kelly M McMasters Journal: J Hematol Oncol Date: 2017-08-29 Impact factor: 17.388
Authors: S Podlipnik; C Carrera; A Boada; N A Richarz; J L López-Estebaranz; F Pinedo-Moraleda; M Elosua-González; M M Martín-González; R Carrillo-Gijón; P Redondo; E Moreno; J Malvehy; S Puig Journal: J Eur Acad Dermatol Venereol Date: 2019-02-28 Impact factor: 6.166